The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.
 
Landon Carter Brown
No Relationships to Disclose
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - Eisai; Ferring
 
Michael Sandon Humeniuk
No Relationships to Disclose
 
Yuan Wu
No Relationships to Disclose
 
Taofik Oyekunle
No Relationships to Disclose
 
Jiaoti Huang
Stock and Other Ownership Interests - Gencode; Genetron Health; KingMed Diagnostics; More Health; Omnitura; Optra SCAN; Sisu Pharmaceuticals; VetOncoRx; York Biotechnology
Honoraria - Abbvie
Consulting or Advisory Role - Gem Flower Healthcare
Research Funding - BioXcell; Fortis; Zenith Epigenetics
Travel, Accommodations, Expenses - Gem Flower Healthcare (I)
 
Monika Anand
No Relationships to Disclose
 
Catrin Davies
Research Funding - Pfizer/EMD Serono; Pfizer/EMD Serono (Inst)
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences; Pacific Genuity
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Astellas Pharma; Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health
 
Michael Roger Harrison
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Fujifilm; Genentech; Janssen Oncology; Pfizer
Speakers' Bureau - Exelixis; Genentech
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Sanofi; Vizuri
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday
 
Andrew J. Armstrong
Honoraria - Astellas Scientific and Medical Affairs Inc
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Dendreon; Merck; Pfizer
Speakers' Bureau - Bayer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc